journal
MENU ▼
Read by QxMD icon Read
search

Annals of Oncology: Official Journal of the European Society for Medical Oncology

journal
https://www.readbyqxmd.com/read/28104621/high-prevalence-of-mutant-kras-in-circulating-exosome-derived-dna-from-early-stage-pancreatic-cancer-patients
#1
K Allenson, J Castillo, F A San Lucas, G Scelo, D U Kim, V Bernard, G Davis, T Kumar, M Katz, M J Overman, L Foretova, E Fabianova, I Holcatova, V Janout, F Meric-Bernstam, P Gascoyne, I Wistuba, G Varadhachary, P Brennan, S Hanash, D Li, A Maitra, H Alvarez
BACKGROUND: Exosomes arise from viable cancer cells and may reflect a different biology than circulating cell-free DNA (cfDNA) shed from dying tissues. We compare exosome-derived DNA (exoDNA) to cfDNA in liquid biopsies of patients with pancreatic ductal adenocarcinoma (PDAC). PATIENTS AND METHODS: Patient samples were obtained between 2003 and 2010, with clinically annotated follow up to 2015. Droplet digital PCR (ddPCR) was performed on exoDNA and cfDNA for sensitive detection of KRAS mutants at codons 12/13...
January 18, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28104620/adjuvant-sunitinib-in-renal-cell-carcinoma-from-evidence-to-recommendation
#2
EDITORIAL
A Bex
No abstract text is available yet for this article.
January 18, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28104619/osimertinib-benefit-in-egfr-mutant-nsclc-patients-with-t790m-mutation-detected-by-circulating-tumour-dna
#3
J Remon, C Caramella, C Jovelet, L Lacroix, A Lawson, S Smalley, K Howarth, D Gale, E Green, V Plagnol, N Rosenfeld, D Planchard, M V Bluthgen, A Gazzah, C Pannet, C Nicotra, E Auclin, J C Soria, B Besse
BACKGROUND: Approximately 50% of Epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs) will acquire resistance by the T790M mutation. Osimertinib is the standard of care in this situation. The present study assesses the efficacy of osimertinib when T790M status is determined in circulating cell-free tumour DNA (ctDNA) from blood samples in progressing advanced EGFR-mutant NSCLC patients. MATERIAL AND METHODS: ctDNA T790M mutational status was assessed by Inivata InVision(TM) (eTAm-Seq(TM)) assay in 48 EGFR-mutant advanced NSCLC patients with acquired resistance to EGFR TKIs without a tissue biopsy between April 2015 and April 2016...
January 18, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28057664/incidence-and-management-of-diarrhea-in-patients-with-her2-positive-breast-cancer-treated-with-pertuzumab
#4
S M Swain, A Schneeweiss, L Gianni, J J Gao, A Stein, M Waldron-Lynch, S Heeson, M S Beattie, B Yoo, J Cortes, J Baselga
BACKGROUND: Pertuzumab disrupts heterodimerization between human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), HER3, and HER4. Thus, pertuzumab could result in adverse events similar to those observed with EGFR antagonists, such as diarrhea. We report the incidence and severity of diarrhea observed with pertuzumab in the CLEOPATRA, NeoSphere, and TRYPHAENA studies. PATIENTS AND METHODS: Patients (n=1443) had metastatic (CLEOPATRA [n=804]) or early-stage breast cancer (NeoSphere [n=416] and TRYPHAENA [n=223])...
January 5, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28057663/parp-inhibitor-and-chemotherapy-combination-trials-for-the-treatment-of-advanced-malignancies-does-a-development-pathway-forward-exist
#5
EDITORIAL
U A Matulonis, B J Monk
Poly (ADP ribose) polymerase (PARP) inhibitor combinations are currently being explored as a treatment strategy for advanced cancers with some or no known DNA repair deficits in order to increase the anti-cancer potential of both the PARP inhibitor and the chemotherapy partner. However, overlapping myelosuppression necessitating lowering of the PARP inhibitor and chemotherapy doses has unknown effects on efficacy. In addition, establishment of pre-clinical efficacy will be critical in moving these combinations rationally forward for further clinical development...
January 5, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28049139/a-randomized-phase-2-study-of-mk-2206-versus-everolimus-in-refractory-renal-cell-carcinoma
#6
E Jonasch, E Hasanov, P Corn, T Moss, K Shaw, S Stovall, V Marcott, B Gan, S Bird, X Wang, K Do, P Altamirano, A Zurita, L Doyle, P Lara, N M Tannir
BACKGROUND: Activation of the phosphoinisitide-3 kinase (PI3K) pathway through mutation and constitutive upregulation have been described in renal cell carcinoma (RCC), making it an attractive target for therapeutic intervention. We performed a randomized phase II study in vascular endothelial growth factor (VEGF) therapy refractory patients to determine whether MK-2206, an allosteric inhibitor of AKT, was more efficacious than the mammalian target of rapamycin inhibitor everolimus. PATIENTS AND METHODS: A total of 43 patients were randomized in a 2:1 distribution, with 29 patients assigned to the MK-2206 arm and 14 to the everolimus arm...
January 3, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28049138/-integrating-communication-as-a-core-skill-in-the-global-curriculum-for-medical-oncology-by-horlait-et-al
#7
LETTER
C Dittrich, F Stiefel, A Kiss, D S Dizon
No abstract text is available yet for this article.
January 3, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28039179/immune-checkpoint-inhibitors-related-orchitis
#8
F Brunet-Possenti, M A Opsomer, L Gomez, I Ouzaid, V Descamps
No abstract text is available yet for this article.
December 29, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28039178/the-natural-history-and-patterns-of-metastases-from-mucosal-melanoma-an-analysis-of-706-prospectively-followed-patients
#9
B Lian, C L Cui, L Zhou, X Song, X S Zhang, D Wu, L Si, Z H Chi, X N Sheng, L L Mao, X Wang, B X Tang, X Q Yan, Y Kong, J Dai, S M Li, X Bai, N Zheng, Charles M Balch, J Guo
BACKGROUND: We examined whether mucosal melanomas are different in their clinical course and patterns of metastases when arising from different anatomic sites. Our hypothesis was that metastatic behavior would differ from primary mucosal melanomas at different anatomical sites. PATIENTS AND METHODS: Clinical and pathological data from 706 patients were compared for their stage distribution, patterns of metastases, CKIT/BRAF mutation status, and overall survival for different anatomical sites...
December 29, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28039177/differential-protein-stability-and-clinical-responses-of-eml4-alkfusion-variants-to-various-alk-inhibitors-in-advanced-alk-rearranged-non-small-cell-lung-cancer
#10
C G Woo, S Seo, S W Kim, S J Jang, K S Park, J Y Song, B Lee, M W Richards, R Bayliss, D H Lee, J Choi
BACKGROUND: Anaplastic lymphoma kinase (ALK) inhibition using crizotinib has become the standard of care in advanced ALK-rearranged non-small cell lung cancer (NSCLC), but the treatment outcomes and duration of response vary widely. Echinoderm microtubule-associated protein-like 4 (EML4)-ALK is the most common translocation, and the fusion variants show different sensitivity to crizotinib in vitro. However, there are only limited data on the specific EML4-ALK variants and clinical responses of patients to various ALK inhibitors...
December 29, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28039176/statistical-controversies-in-clinical-research-publication-bias-evaluations-are-not-routinely-conducted-in-clinical-oncology-systematic-reviews
#11
D Herrmann, P Sinnett, J Holmes, S Khan, C Koller, M Vassar
BACKGROUND: Publication bias is an over-representation of statistically significant results in the published literature and may exaggerate summary effect estimates in oncology systematic reviews. Omitting non-significant results in systematic reviews may therefore affect clinical decision making. We investigate ways that systematic reviewers attempted to limit publication bias during the search process as well as the statistical methods used to evaluate it. For a subset of reviews not reporting publication bias evaluations, we performed our own assessments for publication bias to determine its likelihood among these reviews...
December 29, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28039175/biomarker-directed-molecularly-targeted-therapy-the-importance-of-prospective-evaluation
#12
EDITORIAL
T E Stinchcombe
No abstract text is available yet for this article.
December 29, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28031175/adjuvant-folfox-cetuximab-in-full-ras-and-braf-wildtype-stage-iii-colon-cancer-patients
#13
J Taieb, R Balogoun, K Le Malicot, J Tabernero, E Mini, G Folprecht, J-L Van Laethem, J-F Emile, C Mulot, S Fratté, C-B Levaché, L Saban-Roche, J Thaler, L N Petersen, J Bridgewater, G Perkins, C Lepage, E Van Cutsem, A Zaanan, P Laurent-Puig
BACKGROUND: RAS mutations have been shown to confer resistance to anti-EGFR treatment. We analyzed the results of the PETACC8 trial (cetuximab + FOLFOX vs FOLFOX) in full RAS and BRAF wildtype (WT) patients (pts) with resected stage III colon cancer. METHODS: Exons 2, 3 and 4 of KRAS and NRAS, and BRAF exons 11 and 15, were sequenced using the Ampliseq colon-lung cancer panel version 2, in PETACC8 trial pts who consented to translational research. The impact of cetuximab on time to recurrence (TTR), disease-free survival (DFS) and overall survival (OS) was investigated in pts with tumors harboring RAS & BRAF WT and RAS mutations...
December 28, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28031174/clinical-characteristics-and-prognostic-factors-of-plasmablastic-lymphoma-patients-analysis-of-135-patients-from-the-lysa-group
#14
E Tchernonog, P Faurie, P Coppo, H Monjanel, A Bonnet, M Algarte Génin, M Mercier, J Dupuis, F Bijou, C Herbaux, A Delmer, B Fabiani, C Besson, S Le Gouill, E Gyan, C Laurent, H Ghesquieres, G Cartron
BACKGROUND: Plasmablastic lymphoma (PBL), initially described in 1997 in the oral cavity of HIV positive patients, is now recognized as a distinct aggressive and rare entity of diffuse large B-cells lymphoma (DLBCL) by the WHO (World Health Organization) classification. Since the original description, others cases have been reported. However, these are largely derived from case reports or small series limiting any definitive conclusions on clinical characteristics and outcome. PATIENTS AND METHODS: The clinical, biological, pathological features and outcome of a cohort including 135 patients with PBL, from LYSA centers in France and Belgium, were reported and analyzed...
December 28, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28031173/preference-for-subcutaneous-or-intravenous-administration-of-rituximab-among-patients-with-untreated-cd20-diffuse-large-b-cell-lymphoma-or-follicular-lymphoma-results-from-a-prospective-randomized-open-label-crossover-study-prefmab
#15
M Rummel, T M Kim, F Aversa, W Brugger, E Capochiani, C Plenteda, F Re, P Trask, S Osborne, R Smith, A Grigg
BACKGROUND: To evaluate patient preference and satisfaction for the subcutaneous (SC) versus intravenous (IV) formulation of rituximab given with chemotherapy in previously untreated patients with CD20+ diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL). PATIENTS AND METHODS: Patients received 8 cycles of rituximab according to 2 schedules: Arm A received 1 cycle rituximab IV (375 mg/m(2)) and 3 cycles rituximab SC (1400 mg) then 4 cycles rituximab IV; Arm B received 4 cycles rituximab IV (375 mg/m(2)) then 4 cycles rituximab SC (1400 mg)...
December 28, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28028034/rapamycin-insensitive-companion-of-mtor-rictor-amplification-defines-a-subset-of-advanced-gastric-cancer-and-is-sensitive-to-azd2014-mediated-mtorc1-2-inhibition
#16
S T Kim, S Y Kim, S J Klempner, J Yoon, N Kim, S Ahn, H Bang, K-M Kim, W Park, S H Park, J O Park, Y S Park, H Y Lim, S H Lee, K Park, W K Kang, J Lee
PURPOSE: Targeting oncogenic genomic aberrations is an established therapeutic strategy in multiple tumor types. Molecular classification has uncovered a number of novel targets, and rapamycin-insensitive companion of mTOR (RICTOR) amplification has been identified in lung cancer. Further investigation assessing the therapeutic potential of RICTOR amplification as a novel target across advanced cancers is needed. PATIENTS AND METHODS: Tumor samples from 640 patients with metastatic solid tumors, primarily gastrointestinal and lung cancers were prospectively subjected to a next-generation sequencing (NGS) assay to identify molecular targets...
December 27, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28028033/interventions-for-preventing-cardiomyopathy-due-to-anthracyclines-a-bayesian-network-meta-analysis
#17
H Abdel-Qadir, G Ong, R Fazelzad, E Amir, D S Lee, P Thavendiranathan, G Tomlinson
BACKGROUND: The relative efficacy of interventions for primary prevention of anthracycline-associated cardiotoxicity is unknown. METHODS: We conducted a systematic review of randomized controlled trials for primary prevention of anthracycline-associated cardiotoxicity in adult cancer patients. We used hierarchal outcome definitions in the following order of priority: (1) composite of heart failure or decline in left ventricular ejection fraction, (2) decline in ejection fraction, or (3) heart failure...
December 26, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28011450/statistical-controversies-in-clinical-research-early-phase-adaptive-design-for-combination-immunotherapies
#18
N A Wages, C L Slingluff, G R Petroni
BACKGROUND: In recent years, investigators have asserted that the 3+3 design lacks flexibility, making its use in modern early-phase trial settings, such combinations and /or biological agents, inefficient. More innovative approaches are required to address contemporary research questions, such as those posed in trials involving immunotherapies. DESIGN: We describe the implementation of an adaptive design for identifying an optimal treatment regimen, defined by low toxicity and high immune response, in an early-phase trial of a melanoma helper peptide vaccine plus novel adjuvant combinations...
December 22, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28011449/association-of-plasma-concentrations-of-branched-chain-amino-acids-with-risk-of-colorectal-adenoma-in-a-large-japanese-population
#19
S Budhathoki, M Iwasaki, T Yamaji, H Yamamoto, Y Kato, S Tsugane
BACKGROUND: Available evidence from animal studies suggests that branched-chain amino acids (BCAAs) may have a protective effect against colorectal carcinogenesis. However, a possible effect of BCAAs against colorectal neoplasia has not been evaluated in humans. Here, we aimed to evaluate whether plasma concentrations of BCAA are associated with the risk of colorectal adenoma (CRA), a precursor lesion of colorectal cancer. PATIENTS AND METHODS: Colorectal adenoma cases and controls were identified from examinees who underwent total colonoscopy as part of a cancer screening program between 2004 and 2005 and responded to self-administered dietary and lifestyle questionnaires...
December 22, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28011448/comparison-of-primary-outcomes-in-protocols-public-clinical-trial-registries-and-publications-the-example-of-oncology-trials
#20
A Perlmutter, V-T Tran, A Dechartres, P Ravaud
BACKGROUND: Protocols are often unavailable to peer-reviewers and readers. To detect outcome reporting bias (ORB), readers usually have to resort to publicly available descriptions of study design such as clinical-trial registries. We compared primary outcomes in protocols, ClinicalTrials.gov and publications of oncology trials and evaluated the use of ClinicalTrials.gov as compared with protocols in detecting discrepancies between planned and published outcomes. METHOD: We searched for phase III oncology trials registered in ClinicalTrials...
December 22, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
journal
journal
30452
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"